Augmented zika and dengue neutralizing antibodies are associated with guillain-Barré syndrome

Vista sencilla de ítem
dc.contributor.authorLynch, Rebecca M.
dc.contributor.authorMantus, Grace
dc.contributor.authorEncinales, Liliana
dc.contributor.authorPacheco, Nelly
dc.contributor.authorLi, Guangzhao
dc.contributor.authorPorras-Ramírez, Alexandra
dc.contributor.authorRico Mendoza, Alejandro
dc.contributor.authorPeng, Jin
dc.contributor.authorRengifo Pardo, Monica
dc.contributor.authorMontoya Cruz, Magelda
dc.contributor.authorHarris, Eva
dc.contributor.authorBethony, Jeffrey Michael
dc.contributor.authorSimon, Gary L.
dc.contributor.authorChang, Aileen
dc.contributor.orcidPorras-Ramírez, Alexandra [0000-0002-0800-1388]
dc.date.accessioned2020-03-16T20:49:58Z
dc.date.available2020-03-16T20:49:58Z
dc.date.issued2019
dc.description.abstractenglishThe role of neutralizing antibodies in Zika-induced Guillain-Barré syndrome (GBS) has not yet been investigated. We conducted a case-control study using sera from the 2016 Zika epidemic in Colombia to determine the neutralizing antibody activity against Zika virus (ZIKV) and dengue virus serotype 2 (DENV2). We observed increased neutralizing antibody titers against DENV2 in ZIKV-infected individuals compared with uninfected controls and higher titers to both ZIKV and DENV2 in ZIKV-infected patients diagnosed with GBS compared with non-GBS ZIKV-infected controls. These data suggest that high neutralizing antibody titers to DENV and to ZIKV are associated with GBS during ZIKV infection.eng
dc.format.mimetypeapplication/pdf
dc.identifier.doihttps://doi.org/10.1093/infdis/jiy466
dc.identifier.instnameinstname:Universidad El Bosquespa
dc.identifier.issn1537-6613
dc.identifier.reponamereponame:Repositorio Institucional Universidad El Bosquespa
dc.identifier.repourlrepourl:https://repositorio.unbosque.edu.co
dc.identifier.urihttps://hdl.handle.net/20.500.12495/2069
dc.language.isoeng
dc.publisherOxford University Pressspa
dc.publisher.journalJournal of infectious diseasesspa
dc.relation.ispartofseriesJournal of infectious diseases, 1537-6613, Vol. 219, Nro. 1, 2019, p. 26-30spa
dc.relation.urihttps://academic.oup.com/jid/article/219/1/26/5064749
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International*
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess
dc.rights.accessrightshttps://purl.org/coar/access_right/c_abf198
dc.rights.creativecommons2018
dc.rights.localAcceso abiertospa
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subject.decsAnticuerpos neutralizantesspa
dc.subject.decsVirus zikaspa
dc.subject.decsVirus del denguespa
dc.subject.keywordsGuillain-Barré syndromespa
dc.subject.keywordsNeutralizing antibodyspa
dc.subject.keywordsFlavivirusspa
dc.titleAugmented zika and dengue neutralizing antibodies are associated with guillain-Barré syndromespa
dc.typearticlespa
dc.type.hasversioninfo:eu-repo/semantics/publishedVersion
dc.type.localartículospa

Archivos

Bloque original
Mostrando 1 - 1 de 1
Miniatura
Nombre:
Lynch R.M., Mantus G., Encinales L., Pacheco N., Li G., Porras A., Mendoza A.R., Peng J., Rengifo-Pardo M., Cruz M.M., Harris E., Bethony J.M., Simon G.L., Chang A.Y.,_2019.pdf
Tamaño:
803.45 KB
Formato:
Adobe Portable Document Format
Descripción:
Descargar
Bloque de licencias
Mostrando 1 - 1 de 1
No hay miniatura disponible
Nombre:
license.txt
Tamaño:
1.71 KB
Formato:
Item-specific license agreed upon to submission
Descripción:
Descargar

Colecciones

Artículos